Achilles Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  ATL 001 / Achilles Therap
    Trial completion date, Trial primary completion date, Metastases:  CHIRON: ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC (clinicaltrials.gov) -  Sep 22, 2023   
    P1/2,  N=50, Recruiting, 
    Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
  • ||||||||||  ATL 001 / Achilles Therap
    Trial completion date, Trial primary completion date, Metastases:  THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) -  Jan 9, 2023   
    P1/2,  N=40, Recruiting, 
    Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Jul 2023 --> Jul 2025 Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
  • ||||||||||  ATL 001 / Achilles Therap
    Trial initiation date:  Long-Term Follow-Up Study of Patients Receiving ATL001 (clinicaltrials.gov) -  Feb 16, 2022   
    P2,  N=90, Not yet recruiting, 
    Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025 Initiation date: Jul 2021 --> Jun 2022
  • ||||||||||  ATL 001 / Achilles Therap
    [VIRTUAL] Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program () -  Mar 11, 2021 - Abstract #AACR2021AACR_606;    
    An approach that targets multiple clonal neoantigens with specific T cells has the potential to demonstrate high specificity and efficacy whilst mitigating the risk of immune escape.Achilles Therapeutics is developing a personalized ACT product, ATL001, to target clonal neoantigens, which are identified using tumor exome sequencing and the PELEUS™ bioinformatics platform...The amalgamation of diverse streams of data requires the development of robust processes and systems for data collection, processing and storage. Furthermore, the evaluation of multiple exploratory endpoints will require integration and modelling of baseline covariates, time-series immune-monitoring and efficacy data, all of which will be described
  • ||||||||||  ATL 001 / Achilles Therap
    Trial completion date, Trial primary completion date, Metastases:  THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) -  Feb 11, 2021   
    P1/2,  N=40, Recruiting, 
    Furthermore, the evaluation of multiple exploratory endpoints will require integration and modelling of baseline covariates, time-series immune-monitoring and efficacy data, all of which will be described Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Jul 2023
  • ||||||||||  ATL 001 / Achilles Therap
    Enrollment change, Metastases:  THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) -  Jan 20, 2021   
    P1/2,  N=40, Recruiting, 
    Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Jul 2023 N=20 --> 40
  • ||||||||||  AT-001 / Applied Therap, ATL 001 / Achilles Therap
    ATL001 (STARLIGHT BALLROOM) -  Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_113;